An open-label, 2-part study to evaluate the effect of ethnic variability on tildrakizumab in Caucasian, Chinese, and Japanese subjects.
Latest Information Update: 18 Nov 2015
At a glance
- Drugs Tildrakizumab (Primary) ; Tildrakizumab (Primary)
- Indications Psoriasis
- Focus Pharmacokinetics
Most Recent Events
- 18 Nov 2015 New trial record